New shingles drug brivudine aims to beat standard treatment in pain battle
NCT ID NCT07099157
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This clinical trial compares two drugs for shingles (herpes zoster): brivudine and famciclovir. The study will enroll 140 adults with acute shingles to see which drug better reduces pain and speeds up healing. Researchers will track pain levels for up to 90 days and monitor for long-term nerve pain. The goal is to find a more effective treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brivudine
What this could lead to
If brivudine works better than famciclovir, it could become a new standard treatment for shingles, reducing pain and the risk of long-term nerve pain.
What could go wrong
This is a Phase 4 trial, so brivudine is already approved, but it may not prove superior to famciclovir. Side effects are possible, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University First Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University Third Hospital
RECRUITINGBeijing, 100191, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xuanwu Hospital, Capital Medical University
NOT_YET_RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••